TITLE

Insulin glargine overdose

AUTHOR(S)
Doğan, Fatma Sarı; Onur, Özge Ecmel; Altınok, Arzu Denizbaşı; Güneysel, Özlem
PUB. DATE
October 2012
SOURCE
Journal of Pharmacology & Pharmacotherapeutics;Oct-Dec2012, Vol. 3 Issue 4, p333
SOURCE TYPE
Academic Journal
DOC. TYPE
Case Study
ABSTRACT
Insulin glargine is a long acting novel recombinant human insulin analogue indicated to improve glycemic control, in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. The time course of action of insulins including insulin glargine may vary between individuals and/or within the same individual. Insulin glargine is given as a 24-h dosing regimen and has no documented half-life or peak effect. Hypoglycemia is the most common adverse effect of insulin, including insulin glargine. As with all insulins, the timing of hypoglycemia may differ among various insulin formulations. We present a case of a 76-year-old male insulin-dependent diabetic patient with refractory hypoglycemia secondary to an intentional overdose of insulin glargine. We would like to highlight the necessity of prolonging IV glucose infusion, for a much longer period than expected from pharmacokinetic properties of these insulin analogues after intentional massive overdose.
ACCESSION #
84535781

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics